Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indinavir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.99 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.99 |
| ▸ | TACR2 | P21452 | 1/20 | 0.99 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.99 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.99 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.99 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indinavir Anhydrous SCHEMBL1176257 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL7752012 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL19760130 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL13039789 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL20099152 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL17787450 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL6908581 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL19460567 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21683359 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 | |
| Indinavir Anhydrous SCHEMBL21578565 | 1.00 | CYP3A4 (0.99) | CYP3A4ABCC3ABCB11ABCB1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 47886 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4744729-A2 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | Deciphera Pharmaceuticals, LLC (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| WO-2026086804-A1 | MULTILAYER-REGULATED GENE EDITING SYSTEM AND USE THEREOF | 自如基因科技（深圳）有限公司 | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| WO-1998017282-A1 | METHODS OF USING SUCROSE OCTASULFATE TO TREAT OR PREVENT ENVELOPED VIRUS INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-30 | — | — | WO | claimed |
| WO-1998014436-A1 | 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-09 | — | — | WO | claimed |
| WO-1998004290-A2 | COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS | PERRINE SUSAN P (US) | 1998-02-05 | — | — | WO | claimed |
| WO-1997042962-A1 | FORMULATION FOR USE IN THE PREVENTION OF PATHOGEN INDUCED DISEASES INCLUDING HIV AND HSV | BERGERON MICHEL G (CA) | 1997-11-20 | — | — | WO | claimed |
| WO-1997029751-A1 | USE OF LEUKOTRIENE B4 OR ITS ANALOGUES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS | VIROCELL INC. (CA) | 1997-08-21 | — | — | WO | claimed |
| WO-1997027180-A1 | ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997027480-A1 | METHOD OF MANAGING THE CHEMOTHERAPY OF PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF HUMAN HIV STRAINS | VIRCO N.V. (BE) | 1997-07-31 | — | — | WO | claimed |
| WO-1997021683-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | claimed |
| WO-1997021685-A1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-06-19 | — | — | WO | claimed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | claimed |